Drugs / barasertib
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01019161 | Nov 2009 → Jun 2010 | acute myeloid leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00926731 | Jun 2009 → Aug 2010 | acute myeloid leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00530699 | Nov 2007 → Aug 2009 | acute myeloid leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00497679 | Aug 2006 → Jul 2007 | cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00338182 | May 2006 → Jun 2008 | neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00497991 | May 2006 → Oct 2009 | myeloid leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00497731 | May 2005 → Jun 2008 | cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01354392 | Sep 2011 → Sep 2013 | lymphoma | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00952588 | Jul 2009 → Jun 2011 | acute myeloid leukemia | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | barasertib | “Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.” PMID 21976672 ↗ Oct 20111“Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.” PMID 23763917 ↗ Jun 2013 |
| Known as | AZD1152 | “Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.” PMID 21976672 ↗ Oct 2011 |
| Known as | BARASERTIB (WHO-DD) | ChEMBL registry synonym — accepted as the source's own label CHEMBL415049 ↗ |
| Known as | C14 AZD1152 | “Drug: C14 AZD1152” NCT01019161 ↗ |
| Action | Inhibit | “the potent and selective Aurora B kinase inhibitor barasertib (AZD1152)” PMID 21976672 ↗ Oct 2011 |
| Modality | Small molecule | — CHEMBL415049 ↗ |
| Route | Intravenous | “48-hour continuous intravenous infusion” NCT00338182 ↗ |
| Target | AURKB | “a selective Aurora B kinase inhibitor” PMID 23763917 ↗ Jun 2013 |